Skip to main content
. 2019 Apr 10;25:119–130. doi: 10.1016/j.molmet.2019.04.003

Figure 1.

Figure 1

Expression of the metabolic enzyme HMGCR is elevated in primary PCa tissues and is associated with poor prognosis. (A) Schematic representation of the MVA pathway. Statins inhibit the rate-limiting enzyme of the pathway, HMGCR. GGPP = geranylgeranyl pyrophosphate. (B) Representative images of a patient-matched normal and malignant prostate tissue pair stained for HMGCR expression. Scale bars = 300 μm (top row) and 100 μm (bottom row). (C) Prostate tumor tissues stained more intensely for HMGCR expression compared to adjacent normal prostate tissue controls. N = 149 matched normal and tumor tissues. p < 0.0001 (McNemar's test). (D) HMGCR expression in prostate tumors was associated with early biochemical relapse (BCR) in patients who were statin non-users. Hazard Ratio (95% confidence interval) = 0.43 (0.24–0.97); p = 0.04 (Log-rank test). (E) HMGCR expression among statin non-users by clinical and pathological features. IQR = interquartile range.